Table 1. Model Inputs for Hepatitis C Cost-Effectiveness Model: Base case, Standard Error and parameter distribution.
| Variable | Mean | SE | Distribution | Reference | |
|---|---|---|---|---|---|
| Transition Probabilities | |||||
| F0-F1 | 0.117 | 0.007 | Beta | [21] | |
| F1-F2 | 0.085 | 0.005 | Beta | [21] | |
| F2-F3 | 0.120 | 0.006 | Beta | [21] | |
| F3-F4 | 0.116 | 0.006 | Beta | [21] | |
| F4-DC | 0.070 | 0.009 | Beta | [22] | |
| F4-HCC | 0.022 | 0.011 | Beta | [23] | |
| DC-HCC | 0.068 | 0.019 | Beta | [24] | |
| DC-LT | 0.023 | 0.007 | Beta | [25] | |
| DC-DTHLR [year 1] | 0.182 | 0.060 | Beta | [22] | |
| DC-DTHLR [year 2] | 0.182 | 0.060 | Beta | [22] | |
| HCC-LT | 0.040 | 0.020 | Beta | [26, 27] | |
| HCC-DTHLR [year 1] | 0.427 | 0.049 | Beta | [28] | |
| HCC-DTHLR [year 2] | 0.427 | 0.049 | Beta | [28] | |
| LT1-DTHLR | 0.116 | 0.029 | Beta | [29] | |
| LT2-DTHLR | 0.044 | 0.010 | Beta | [29] | |
| F4-SVR-DC | 0.008 | 0.003 | Beta | [30] | |
| F4-SVR-HCC | 0.005 | 0.002 | Beta | [30] | |
| Costs a Adverse event costs | |||||
| Anemia | $ 13,000 | ±30% | Gamma | [31, 32] | |
| Rush & Pruritus | $ 1,033 | ±30% | Gamma | [31, 32] | |
| Depression | $ 3,366 | ±30% | Gamma | [31, 32] | |
| Hepatitis C drug prices [whole treatment] | |||||
| DCV/ASV | $ 38,710 | ±30% | Gamma | Base case price | |
| PR | $ 11,034 | ±30% | Gamma | [31] | |
| PIs/PR b | $ 30,336 | ±30% | Gamma | [33] | |
| Monitoring costs [per week] | |||||
| Week 0-24-48 | $ 107 | ±30% | Gamma | [31] | |
| Week 2–4 | $ 125 | ±30% | Gamma | [31] | |
| Week 8-16-20-28-32-40-44 | $ 18 | ±30% | Gamma | [31] | |
| Week 12 | $ 62 | ±30% | Gamma | [31] | |
| Disease related costs | |||||
| SVR [F0-F3] year 1 | $ 56 | ±30% | Gamma | [31, 34] | |
| SVR [F0-F3] year 2 | $ 19 | ±30% | Gamma | [31] | |
| SVR F4 year 1 | $ 56 | ±30% | Gamma | [31, 34] | |
| SVR F4 year 2 | $ 325 | ±30% | Gamma | [31, 34] | |
| F0-F1-F2 | $ 190 | ±30% | Gamma | [31, 34] | |
| F3 | $ 282 | ±30% | Gamma | [31, 34] | |
| F4 | $ 420 | ±30% | Gamma | [31, 34] | |
| DC1 | $ 3049 | ±30% | Gamma | [24, 31, 32] | |
| DC2 | $ 2,489 | ±30% | Gamma | [24, 31, 32] | |
| HCC1 | $ 1,408 | ±30% | Gamma | [32] | |
| HCC 2+ | $ 956 | ±30% | Gamma | [31, 32] | |
| LT1 | $ 60,259 | ±30% | Gamma | [35, 36] | |
| LT 2+ | $ 8,262 | ±30% | Gamma | [31, 35, 36] | |
| Local utility measure c | N° patients | Mean | SE | Distribution | Reference |
| F0-F3 | 2 | 0.686 | ±30% | Beta | [20] |
| F4 | 9 | 0.682 | 0.285 | Beta | [20] |
| DC | 2 | 0.536 | ±30% | Beta | [20] |
| HCC | 4 | 0.952 | 0.096 | Beta | [20] |
| LT1 | 1 | 0.572 | ±30% | Beta | [20] |
| LT2+ | 2 | 0.904 | ±30% | Beta | [20] |
| SVR F0-F1 | 5 | 1 | 0 | Beta | [20] |
| SVR F2-F3 | 2 | 1 | 0 | Beta | [20] |
| SVR—F4 | 1 | 0.798 | ±30% | Beta | [20] |
| Literature utility measure | |||||
| F0-F1 | 0.77 | 0.19 | Beta | [37] | |
| F2-F3 | 0.66 | 0.15 | Beta | [37] | |
| F4 | 0.55 | 0.11 | Beta | [37] | |
| DC | 0.45 | 0.10 | Beta | [37] | |
| HCC | 0.45 | 0.10 | Beta | [37] | |
| LT1 | 0.45 | 0.10 | Beta | [37] | |
| LT2+ | 0.67 | 0.14 | Beta | [37] | |
| SVR F0-F1 | 0.82 | 0.19 | Beta | [37] | |
| SVR F2-F3 | 0.72 | 0.16 | Beta | [37] | |
| SVR—F4 | 0.72 | 0.16 | Beta | [37] | |
| SVR | |||||
| DCV/ASV | 0.945 | 0.023 | Beta | [19] | |
| PR | 0.489 | 0.018 | Beta | [19] | |
| PI | 0.736 | 0.052 | Beta | [19] | |
SE: Standard Error, PR: Peginterferon plus Ribavirin, PIs: Protease Inhibitors, DCV/ASV: Daclatasvir plus Asunaprevir, QALY: Quality Adjusted Life Years, DC: Decompensated Cirrhosis, HCC: Hepatocellular carcinoma, LT: Liver transplant, SVR: Sustained viral response, DTHLR: Disease specific death, CENABAST: National public drug supplier
aAll costs were adjusted to 2014 US dollars and rounded to the nearest hundred.
b Price corresponds to the average 2014 price.
cEQ-5D survey to local patients was valued using Chilean published tariff.